What is HC Wainwright’s Forecast for EIKN Q3 Earnings?

Eikon Therapeutics, Inc. (NASDAQ:EIKN) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Eikon Therapeutics in a research note issued on Friday, October 16th. HC Wainwright analyst S. Nik expects that the company will post earnings per share of ($1.72) for the quarter. HC Wainwright currently has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Eikon Therapeutics’ current full-year earnings is ($7.24) per share. HC Wainwright also issued estimates for Eikon Therapeutics’ Q4 2026 earnings at ($1.82) EPS, FY2026 earnings at ($7.40) EPS, FY2027 earnings at ($8.49) EPS and FY2028 earnings at ($3.70) EPS.

Eikon Therapeutics (NASDAQ:EIKN) last announced its earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02).

A number of other research analysts have also issued reports on the stock. Wedbush lowered their target price on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a research note on Friday, August 14th. Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a report on Wednesday, September 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Eikon Therapeutics Stock Performance

Shares of Eikon Therapeutics stock opened at $7.70 on Tuesday. The firm has a fifty day simple moving average of $9.37 and a 200-day simple moving average of $9.91. Eikon Therapeutics has a 1-year low of $6.45 and a 1-year high of $17.40.

Insider Transactions at Eikon Therapeutics

In related news, major shareholder Group Iv Gp Lp Column purchased 89,200 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were bought at an average cost of $11.56 per share, for a total transaction of $1,031,152.00. Following the transaction, the insider directly owned 89,200 shares of the company’s stock, valued at approximately $1,031,152. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after acquiring an additional 962,046 shares during the period. State Street Corp bought a new stake in shares of Eikon Therapeutics in the 2nd quarter worth approximately $4,621,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Eikon Therapeutics during the 2nd quarter worth approximately $3,341,000. Comprehensive Financial Management LLC acquired a new stake in shares of Eikon Therapeutics during the 2nd quarter worth approximately $1,517,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Eikon Therapeutics during the second quarter valued at approximately $624,000.

Eikon Therapeutics Company Profile

Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines using advanced single-molecule imaging, cell biology and computational technologies. Its platform is designed to track the behavior of proteins and other molecular targets in living cells, with the goal of improving the understanding of disease biology and identifying potential drug candidates.

The company is developing a pipeline of therapeutics, including investigational treatments in areas such as oncology and other serious diseases.